文献速递慢性肾脏病遗传性与小管间质肾病

SPRINT 研究中肾小管损伤与功能障碍尿液标志物与衰弱指数及认知功能的关联

Association of Urine Biomarkers of Kidney Tubule Injury and Dysfunction With Frailty Index and Cognitive Function in Persons With CKD in SPRINT.
PubMed 文献 · Am J Kidney Dis · 2021-02-27

该研究为 SPRINT 试验中 2253 例 eGFR<60mL/min/1.73m2 的 CKD 患者横断面分析,评估 8 种尿液肾小管标志物与衰弱指数及认知功能的关联。结果发现尿 KIM-1、MCP-1 和 A1M 独立关联衰弱,尿 B2M 关联认知评分较差,且独立于 eGFR 和尿白蛋白。

要点

  • 尿 KIM-1、MCP-1、A1M 每倍增与衰弱组几率分别增加 22%、30%、48%。
  • 尿 B2M 升高与基线认知评分较差独立相关(β=-0.09)。
  • 肾小管标志物与衰弱/认知的关联独立于 eGFR 和尿白蛋白。

核心结论

  • 肾小管损伤、纤维化及近端小管重吸收功能的尿液标志物与衰弱和认知功能下降存在不同程度的独立关联。

研究设计与样本

  • SPRINT 试验中 2253 例 eGFR<60mL/min/1.73m2 参与者的观察性横断面研究。

主要发现

  • 尿 KIM-1 每 2 倍升高与衰弱组几率增加相关(OR 1.22,95%CI 1.01-1.49)。
  • 尿 MCP-1 每 2 倍升高与衰弱组几率增加相关(OR 1.30,95%CI 1.04-1.64)。
  • 尿 A1M 每 2 倍升高与衰弱组几率增加相关(OR 1.48,95%CI 1.11-1.96)。
  • 尿 B2M 升高与基线认知评分较差相关(β -0.09,95%CI -0.17 至 -0.01)。
  • 尿白蛋白与衰弱关联较弱(OR 1.15,95%CI 0.99-1.34),与认知功能无显著关联。

关键数值与推荐

  • 衰弱指数分类:健康 FI≤0.10,较不健康 0.10<FI≤0.21,衰弱 FI>0.21。
  • 认知功能采用蒙特利尔认知评估(MoCA)量表评估。

临床怎么用

  • 在 CKD 患者中可考虑检测尿 KIM-1、MCP-1、A1M、B2M 以辅助评估衰弱和认知风险。

局限性

  • 横断面设计无法推断因果关系。
  • 衰弱指数可能不适用于其他人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: The associations of the glomerular markers of kidney disease, estimated glomerular filtration rate (eGFR) and albuminuria, with frailty and cognition are well established. However, the relationship of kidney tubule injury and dysfunction with frailty and cognition is unknown. STUDY DESIGN: Observational cross-sectional study. SETTING & PARTICIPANTS: 2,253 participants with eGFR<60mL/min/1.73m2 in the Systolic Blood Pressure Intervention Trial (SPRINT). EXPOSURE: Eight urine biomarkers: interleukin 18 (IL-18), kidney injury molecule 1 (KIM-1), neutrophil gelatinase-associated lipocalin (NGAL), chitinase-3-like protein 1 (YKL-40), monocyte chemoattractant protein 1 (MCP-1), α1-microglobulin (A1M), β2-microglobulin (B2M), and uromodulin (Umod). OUTCOME: Frailty was measured using a previously validated frailty index (FI), categorized as fit (FI≤0.10), less fit (0.10<FI≤0.21), and frail (FI>0.21). Cognitive function was assessed using the Montreal Cognitive Assessment (MoCA). ANALYTICAL APPROACH: Associations between kidney tubule biomarkers with categorical FI were evaluated using multinomial logistic regression with the fit group as the reference. Cognitive function was evaluated using linear regression. Models were adjusted for demographic, behavioral, and clinical variables including eGFR and urine albumin. RESULTS: Three of the 8 urine biomarkers of tubule injury and dysfunction were independently associated with FI. Each 2-fold higher level of urine KIM-1, a marker of tubule injury, was associated with a 1.22 (95% CI, 1.01-1.49) greater odds of being in the frail group. MCP-1, a marker of tubulointerstitial fibrosis, was associated with a 1.30 (95% CI, 1.04-1.64) greater odds of being in the frail group, and A1M, a marker of tubule reabsorptive capacity, was associated with a 1.48 (95% CI, 1.11-1.96) greater odds of being in the frail group. These associations were independent of confounders including eGFR and urine albumin, and were stronger than those of urine albumin with FI (1.15 [95% CI, 0.99-1.34]). Higher urine B2M, another marker of tubule reabsorptive capacity, was associated with worse cognitive scores at baseline (β: -0.09 [95% CI, -0.17 to-0.01]). Urine albumin was not associated with cognitive function. LIMITATIONS: Cross-sectional design, and FI may not be generalizable in other populations. CONCLUSIONS: Urine biomarkers of tubule injury, fibrosis, and proximal tubule reabsorptive capacity are variably associated with FI and worse cognition, independent of glomerular markers of kidney health. Future studies are needed to validate these results among other patient populations.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Miller LM, Rifkin D, Lee AK, et al. Association of Urine Biomarkers of Kidney Tubule Injury and Dysfunction With Frailty Index and Cognitive Function in Persons With CKD in SPRINT. Am J Kidney Dis. 2021. PMID: 33647393. doi:10.1053/j.ajkd.2021.01.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。